Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 3:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 569 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Clear all
Completed Phase 2 Interventional Results available

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

NCT03006302
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Epacadostat, Pembrolizumab, CRS-207, Cyclophosphamide, GVAX Pancreas Vaccine
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 3 Interventional

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

NCT00265837
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 11, 2026, 3:35 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

NCT00616967
View directory record Official record
Conditions
Breast Cancer
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat, placebo
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Annapolis, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas

NCT01595321
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX Pancreas Vaccine, Stereotactic Body Radiation, FOLFIRINOX
Drug · Biological · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 76 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

NCT04098068
View directory record Official record
Conditions
High Tumor Mutation Burden, High TMB (Tumor Mutation Burden), MSS (Microsatellite Stable)
Interventions
MK-3475
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 1 Interventional Results available

Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

NCT03246074
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fostamatinib 100 mg bid and Paclitaxel, Fostamatinib 150 mg bid and Paclitaxel, Fostamatinib 200 mg bid and Paclitaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study

NCT04499950
View directory record Official record
Conditions
Breast Cancer, Overweight or Obesity
Interventions
Contrave, Behavioral Weight Loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 11, 2026, 3:35 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

NCT01937117
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron emission tomography (PET), Trastuzumab, Pertuzumab
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 11, 2026, 3:35 AM EDT
Terminated Not applicable Interventional Results available

Iodine I 131 in Treating Patients With Thyroid Cancer

NCT00416949
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Patient-specific dosimetry
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 11, 2026, 3:35 AM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

NCT06508138
View directory record Official record
Conditions
HPV 16 Infection, HPV-Related Carcinoma, Recurrence, Metastatic Cancer
Interventions
pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

NCT04301778
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Durvalumab, SNDX-6352
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 11, 2026, 3:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

NCT03465592
View directory record Official record
Conditions
Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
Interventions
Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Months to 40 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
4
States / cities
St. Petersburg, Florida • Baltimore, Maryland • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

NCT02601014
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Ipilimumab, Nivolumab, Enzalutamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 11, 2026, 3:35 AM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

NCT03767582
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions
Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist, GVAX
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

NCT04177810
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Cemiplimab, Plerixafor
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 11, 2026, 3:35 AM EDT
Recruiting Phase 1 Interventional

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

NCT04245397
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
SX-682, Decitabine
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
7
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559
View directory record Official record
Conditions
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions
DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod
Biological · Device · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 11, 2026, 3:35 AM EDT
Recruiting Phase 2 Interventional

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 11, 2026, 3:35 AM EDT
Terminated Phase 2 Interventional Results available

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

NCT00072449
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 1 Interventional

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

NCT02716948
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine, Stage IV Skin Melanoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
Other · Biological · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 11, 2026, 3:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Partial Breast Irradiation With Chemotherapy

NCT00278109
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, Doxorubicin, radiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
40 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 11, 2026, 3:35 AM EDT
Terminated Phase 3 Interventional

Modafinil in Opioid Induced Sedation

NCT00267332
View directory record Official record
Conditions
Cancer, Pain
Interventions
Modafinil
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 11, 2026, 3:35 AM EDT
Terminated Phase 2 Interventional Results available

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

NCT00867308
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Lenalidomide 50 mg, Lenalidomide 15 mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 11, 2026, 3:35 AM EDT